134 related articles for article (PubMed ID: 28058710)
1. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma.
Liu MY; Lo CH; Lin CS; Chao HL; Yang JF; Lin KT; Fan CY; Su YF; Huang WY
Tumori; 2017 May; 103(3):236-241. PubMed ID: 28058710
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
[TBL] [Abstract][Full Text] [Related]
3. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
Tao R; Krishnan S; Bhosale PR; Javle MM; Aloia TA; Shroff RT; Kaseb AO; Bishop AJ; Swanick CW; Koay EJ; Thames HD; Hong TS; Das P; Crane CH
J Clin Oncol; 2016 Jan; 34(3):219-26. PubMed ID: 26503201
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization.
Lo CH; Huang WY; Lee MS; Lin KT; Lin TP; Chang PY; Fan CY; Jen YM
Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):345-52. PubMed ID: 24384685
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
[TBL] [Abstract][Full Text] [Related]
8. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review.
Lee J; Yoon WS; Koom WS; Rim CH
Strahlenther Onkol; 2019 Feb; 195(2):93-102. PubMed ID: 30206644
[TBL] [Abstract][Full Text] [Related]
10. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
11. Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma.
Kaiser GM; Frühauf NR; Lang H; Sauerwein W; Sotiropoulos GC; Zöpf T; Grabellus F; Wittig A; Oldhafer KJ; Malagó M; Broelsch CE
Hepatogastroenterology; 2008; 55(88):1951-4. PubMed ID: 19260456
[TBL] [Abstract][Full Text] [Related]
12. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
[TBL] [Abstract][Full Text] [Related]
13. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
14. Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma.
Lo CH; Huang WY; Lin KT; Lin MJ; Lin TP; Jen YM
J Gastroenterol Hepatol; 2014 Nov; 29(11):1919-25. PubMed ID: 25041220
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Kopek N; Holt MI; Hansen AT; Høyer M
Radiother Oncol; 2010 Jan; 94(1):47-52. PubMed ID: 19963295
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
17. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
Saxena A; Bester L; Chua TC; Chu FC; Morris DL
Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
[TBL] [Abstract][Full Text] [Related]
18. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.
Zhang XX; Ma HB; Li TH; Huang B; Jia NY; Meng Y
Clin Transl Oncol; 2023 Mar; 25(3):731-738. PubMed ID: 36401766
[TBL] [Abstract][Full Text] [Related]
19. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma.
Ben-David MA; Griffith KA; Abu-Isa E; Lawrence TS; Knol J; Zalupski M; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):772-9. PubMed ID: 17011452
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G
Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
